Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Has results × Neurofibromatoses × Clear all

Phase

Phase 2 6 Phase EARLY_PHASE1 1 Phase 4 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 171 Breast Neoplasms 168 Neoplasms 147 Leukemia, Myeloid, Acute 136 Multiple Myeloma 132 Neoplasm Metastasis 100 Lymphoma 100 Melanoma 99 Prostatic Neoplasms 98 Leukemia 94 Lymphoma, Non-Hodgkin 87 Colorectal Neoplasms 82 Recurrence 75 Pancreatic Neoplasms 75 Ovarian Neoplasms 75 Lung Neoplasms 72 Leukemia, Lymphocytic, Chronic, B-Cell 72 Glioblastoma 72 Myelodysplastic Syndromes 68 Precursor Cell Lymphoblastic Leukemia-Lymphoma 64 Lymphoma, Follicular 64 Lymphoma, Large B-Cell, Diffuse 61 Hodgkin Disease 55 Carcinoma, Renal Cell 55 Lymphoma, Mantle-Cell 53 Brain Neoplasms 52 Carcinoma, Hepatocellular 47 Squamous Cell Carcinoma of Head and Neck 45 Sarcoma 44 Triple Negative Breast Neoplasms 43

Interventions

Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01140360 2017-07-02

0908-09

Indiana University

Phase 1/2 Completed

21 enrolled 8 charts

Neurofibroma, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon ⚡